As investors, we need to understand how our companies truly make their money. A neat trick developed for just that purpose -- the DuPont Formula -- can help us do so.

The DuPont Formula can give you a better grasp on exactly where your company is producing its profit, and where it might have a competitive advantage. Named after the company where it was pioneered, the formula breaks down return on equity into three components:

        Return on equity = net margin x asset turnover x leverage ratio

What makes each of these components important?

  • High net margins show that a company can get customers to pay more for its products. Luxury-goods companies provide a great example here.
  • High asset turnover indicates that a company needs to invest less of its capital, since it uses its assets more efficiently to generate sales. Service industries, for instance, often lack big capital investments.
  • Finally, the leverage ratio shows how much the company is relying on liabilities to create its profits.

Generally, the higher these numbers, the better. That said, too much debt can sink a company, so beware of companies with very high leverage ratios.

Let's see what the DuPont Formula can tell us about Novartis (NYSE: NVS) and a few of its sector and industry peers:


Return on Equity

Net Margin

Asset Turnover

Leverage Ratio






sanofi-aventis (NYSE: SNY)





AstraZeneca (Nasdaq: AZN)





Teva Pharmaceutical (Nasdaq: TEVA)





Source: Capital IQ, a division of Standard & Poor's.

Novartis achieves a solid ROE with numbers that sit right in the middle of its peers'. Teva looks much the same as Novartis, according to these figures. However, sanofi's numbers are just a bit lower in each category, leading to a much a less attractive return on equity. AstraZeneca's ROE is much more impressive, and its focus on high net margins, asset turnover, and leverage show why. 

Using the DuPont formula can often give you some insight into how a company is competing against peers and what type of strategy it's using to juice return on equity. To find more successful investments, dig deeper than the earnings headlines. If you'd like to add these companies to your watchlist, or set up a new one, just click here.

Jim Royal, Ph.D., does not own shares in any company mentioned. Novartis and Teva Pharmaceutical are Motley Fool Global Gains recommendations. The Fool owns shares of Teva. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.